Bluejay completes Toray milestone: what the deadline means for Bluejay Diagnostics stock

Published on 10/19/2026 at 01:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 23, 2026 contractual deadline was met early on October 13, 2026. For Bluejay Diagnostics stock, reported cash stood at USD 9.6 million on June 30, 2026.

Clinical and financial milestones

Bluejay Diagnostics completed its Toray manufacturing milestone on October 13, 2026, ahead of the October 23 deadline.
The October 6, 2026 SYMON-II dataset covered 777 patients, including 140 non-survivors at 28 days.
Bluejay reported USD 9.6 million in cash and cash equivalents as of June 30, 2026.

Bluejay, US0956336087, Illustration mit AI erstellt.

Bluejay Diagnostics (ISIN US0956336087) completed a manufacturing-site milestone under its amended Toray license agreement on October 13, 2026. According to StockTitan, the company established a Japanese site for Symphony cartridges ahead of the October 23 contractual deadline.

What the milestone changes

The site is intended to support manufacturing scale-up for Bluejay's Symphony IL-6 test as the company works toward a regulatory submission. The filing identifies SanyoSeiko in Japan as the site established under the Toray agreement and also describes a U.S. manufacturing relationship with ALURIS Sciences.

The commercial opportunity remains tied to regulatory execution. The same filing states that the Symphony IL-6 test has not been cleared or approved by the U.S. Food and Drug Administration and is not available for commercial clinical use in the United States.

Three dates show the progression

On July 21, 2026, Bluejay reported SYMON-II enrollment of 750 patients; on October 6, 2026, its preliminary dataset reached 777 evaluable patients with 140 non-survivors at 28 days; and on October 13, 2026, it completed the manufacturing milestone ahead of the October 23 deadline, according to StockTitan.

Which dates matter next

October 23, 2026 is the contractual deadline cited in the Toray agreement. MarketBeat lists November 13, 2026 as the estimated next earnings date.

Liquidity remains a central risk

Bluejay reported USD 9.6 million in cash and cash equivalents as of June 30, 2026, alongside a USD 4.24 million net loss for the first six months of 2026, according to the Worcester Business Journal. The report also said the company expected to need USD 10.0 million to USD 14.0 million of additional capital through the end of fiscal year 2027 to execute its commercialization plan.